Summary 1,25 dihydroxyvitamin D3, the active form of vitamin D, has immunomodulatory properties in vitro and in vivo. We report that treatment with 1,25 dihydroxyvitamin 03 (5 gg/kg on alternate days) prevents the development of clinical diabetes in NOD mice, an animal model of human autoimmune diabetes. Diabetes incidence in female NOD mice at the age of 200 days was reduced to 8 % in the 1,25 dihydroxyvitamin D treated group vs 56% in the control group (p < 0.0001). In parallel, treatment with 1,25 dihydroxyvitamin D 3 resulted in a complete normalisation of the capacity to induce suppressor mechanisms in an autologous MLR, which is severely depressed in control NOD mice. The existence of such suppressor ceils was confirmed in transfer experiments, whereby cotransfer of splenocytes from 1,25 dihydroxyvitamin D3 treated NOD mice prevented diabetes transfer by splenocytes from diabetic NOD mice into irradiated, 6-8-week-old male NOD mice. Other known immune defects of the NOD mice, such as defective natural killer cell killing of YAC-1 targets and defective thymocyte activation by anti-CD3 were not corrected. The pharmacological doses of 1,25 dihydroxyvitamin D3 were universally well tolerated as reflected by a normal weight gain of the mice. Serum calcium was increased (2.5+0.2 vs 2.2 + 0.2 mmol/1 in the control group,p < 0.005), whereas osteocalcin levels nearly doubled and bone calcium content was halved. These findings show that 1,25 dihydroxyvitamin D3 can prevent diabetes in NOD mice, probably through the correction of their defective suppressor function. [Diabetologia (1994) 37: 552-558] 
The NOD mouse is an animal model for human autoimmune diabetes (IDDM or juvenile diabetes), characterized by destruction of the insulin producing beta cells of the islets of Langerhans in the pancreas. The precise immune mechanisms leading to this destruction remain unclear [1] [2] [3] . Defective elimination of autoreactive T-cell clones or impaired suppressor mechanisms are the most acceptable hypotheses [4] . ConseReceived: 21 October 1993 and in revised form: 27 December 1993 quently, prevention of the disease might be achieved through immunomodulation, preferentially by drugs that are able to block effector T lymphocytes or stimulate suppressor function. Both capacities have been attributed to 1,25(OH)2D3, the activated form of vitamin D [5] [6] . Receptors for 1,25(OH)2D3 have been described in cells of the immune system [7] [8] .
In vitro, 1,25(OH)2D3 suppresses both effector Tlymphocyte proliferation [9] and lymphokine secretion (interleukin-2, interferon 7/and tumour necrosis factor ~) [10] [11] [12] [13] and it enhances suppressor function [14] . Also in vitro, monocyte differentiation and macrophage function are stimulated, but data on effects of 1,25(OH)2D3 on monokine production and accessory cell function are still inconclusive [15] [16] . In vivo, 1,25(OH)2D3 is able to prevent autoimmune diseases such as experimental allergic encephalomyelitis and allergic thyroiditis [17] [18] . A major problem remaining however, is the hypercalcaemia induced by the pharmacological doses of this hormone/vitamin, required to obtain these effects. Therefore, most in vivo treatment protocols are short term and deal with experimentallyinduced diseases. In a pilot experiment we demonstrated that 1,25(OH)2D3 can prevent insulitis, the histopathological lesion of spontaneous autoimmune diabetes, in NOD mice. The long-term treatment with pharmacological doses of 1,25(OH)2D3 (5 ~tg/kg) was well tolerated when the drug was administered on alternate days and when the animals were fed a low calcium diet [19] . However, the exact mode of action of the substance in the prevention of autoimmunity remains unclear.
The aim of this study was to evaluate the effects of 1,25 (OH)2D3 on the incidence of clinical diabetes in the NOD mouse and to investigate the immune effects of long-term treatment with 1,25 (OH)2D3.
Materials and methods

Animals
NOD mice that were originally obtained from Professor Wu (1990, B eijing, China), were bred in our animalium (Proefdierencentrum Leuven) and kept under conventional conditions. Animals were fed a low-calcium, vitamin D replete diet (0.2 % calcium, 1% phosphate, 2000 U vitamin D/kg; Hope Farms, Woerden, The Netherlands). C3H and C57B1/6 mice were purchased from Charles River (Wiga, Sulzfeld, Germany). Diabetes incidence at the age of 200 days in stock mice at the time of the study was 57 % in female and 22 % in male mice. After the age of 200 days, the diabetes incidence in the colony was less than 0.5 %. In this study only female NOD mice were used.
Treatment regimen
1,25(OH)2D 3 was kindly provided by M. Uskokovic (HoffmanLa Roche, Nutley, N J, USA) and was dissolved in arachis oil. Animals were divided into two groups: test animals (n = 40) received 1,25 (OH)2D 3 (5 gg/kg) in 0.05 ml arachis oil intraperitoneally every other day, while the control group (n = 40) received arachis oil (0.05 ml) only. Treatment was started at the age of 21 days and terminated at the age of 200 days or on the day of diabetes diagnosis.
Evaluation of disease and insulitis
Mice were weighed weekly and glucosuria was tested three times per week starting from the age of 70 days using Ketodiabur Stix (Boehringer Mannheim, Mannheim, Germany). Diabetes was diagnosed in mice having positive glucosuria and glycaemia above 13.8 mmol/1 on two consecutive days. Glycaemia was measured on a Glucoscot II Glucometer (Menarini, Firenze, Italy). Due to injection accidents, four 1,25(OH)zD3 treated mice (10%) and eight of the control mice (20%) died. These mice were excluded from evaluation. At diabetes diagnosis or at 200 days of age, mice were killed by ether inhalation and cervical dislocation (24 h after the final injection). Pancreata were removed, fixed in Bouin's solution, embedded in paraffin and serial sections of the whole pancreas were madel Sections were 553 stained with haematoxylin eosin. Insulitits was evaluated by two independent investigators. A mean of 30islets per pancreas were screened and the level of lymphocytic infiltration in the islets was scored as described previously [I9] . Briefly, the following scoring system was used: 0, no lymphocytes in or around the islets; 1, periductular infiltrate; 2, peri-islet infiltrate; 3, intraislet infiltrate; 4, intra-islet infiltrate associated with beta-cell destruction. The mean score for each pancreas was calculated by dividing the total score by the number of islets scored. Any degree of lymphocytic infiltration ( > 0) was scored as positive.
Evaluation of calcaemic effects of l,25(OH)2D3
At the age of 200 days or at diabetes diagnosis, blood was taken by heart puncture. Calcium was determined by microcolorimetric assay (Sigma, St. Louis, Mo., USA) and serum osteocalcin was determined by an in-house radioimmunoassay that used mouse osteocalcin as standard and a polyclonal guinea pig antimouse osteocalcin antiserum. The within and between assay variation coefficients were 4 and 6 %, respectively, and the sensitivity was 0.02 nmol/1 (R. Bouillon, unpublished observations). Calcium content in the tibia was measured as calcium in bone ash dilutions as described previously [20] .
Immunological tests
Mixed lyrnphocyw reaction: spleens were removed aseptically, gently teased apart and pressed through a steel mesh. Splenocytes of test animals (5 x 106/ml; 5 x 105 cells per well) were cocultured after T-cell enrichment by nylon wool passage with irradiated (3000 Rad, 6~ source) splenocytes from C57B1/6 mice as stimulators (5x 106/ml; 5• 105 cells per well), in RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10 % fetal calf serum, glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin and 0.2 % mercapto-ethanol for 5 days. Cells were cultured in triplicate in flat-bottomed 96-well microfitre tissue culture plates (Nunc, Roskilde, Denmark). Cells were pulsed after 4 days with 1 gCi of [methyl-3H]thymidine (Radiochemical Center Amersham, Buckinghamshire, UK), harvested 18 h later on glass filter paper and counted. Stimulation index was calculated according to the following formula: SI = cpm (responders + sfimulators)/cpm (responders) x 100.
Anti-CD3 stimulation
Splenocytes (1 x 106/ml; 2 x 105 cells per well) or thymocytes (1 x 106/mi; 2 x 105 cells per well) were cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum, glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin and 0.2 % mercapto-ethanol. Cells were cultured in triplicate in flat-bottomed 96-well microtitre tissue culture plates (Nunc, Roskilde, Denmark) in the presence of soluble anti-CD3 monoclonal antibody (17 ~tg/ml) (a kind gift of J. Plum, University of Ghent, Belgium) for 72 h. [Methyl-3H]thymidine incorporation was measured after 18 h and SI were calculated.
Natural killer cell activity
As target cells YAC-1 tumour cells (ATCC) were used. For labelling, lx106 YAC-1 cells were resuspended in 0.4ml RPMI 1640 with 5 % fetal calf serum and 200 gCi 51Cr (Radiochemical Center) and incubated at 37 ~ for 60 min in a CO2 incubator. Thereafter target cells were washed three times and splenocytes by nylon wool passage, were co-cultured with 6~ irradiated (3000 Rad) splenic leucocytes from the same animal (5x 106/ml; 5x105 per well), in RPMI1640 medium supplemented with 10 % fetal calf serum, glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin and 0. On day 200 or the day of diabetes diagnosis, animals were bled by heart puncture. Serum calcium and osteocalcin were determined as well as bone calcium content per tibia, as described in Materials and methods. Mean values + SD are shown were adjusted to a concentration of i x 105 cells per ml in 10 ml RPMI 1640 with 10% fetal calf serum, glutamine, 100 U/ml penicillin and 100 gg/ml streptomycin.
Splenocytes (5 x 106/mi; 5 x 105 per well) were added as effector cells to 1 x 10451Cr-labelled target cells in a final volume of 0.2ml of RPMI 1640 with t0% fetal calf serum, glutamine, 100 U/ml penicillin and 100 gg/ml streptomycin per well (effectot: target ratio 50:1). Cells were cultured in quadruplicate in 96-well V-bottom microtitre plates (Nunc) for 4 h at 37~ in a CO; incubator. 5iCr release was measured in the supernatant. Spontaneous release of 51Cr was obtained by monitoring radioactivity released during the incubation of 1 x 104 target cells alone. Maximum release of 51Cr was determined by monitoring radioactivity released after the addition of a detergent (saponin) to lyse the target cells. Percent of specific lysis was calculated according to the following formula: percent specific lysis= [(CPM experimental -CPM spontaneous release)/(CPM maximum release -CPM spontaneous release)] x 100.
Suppressor cell assay
The capacity to generate suppressor cells in an autologous MLR was tested as described previously [21] . Briefly, T cells (5 x 106/ml; 5 x 105 per well) from the test animal, enriched from For diabetes transfer, naive 6-8-week-old male NOD mice, were irradiated (750 Rad) and, 48 h after irradiation received 20 x 106 splenocytes, obtained as described above, from overtly diabetic NOD mice i.v. In co-transfer experiments, 20 x 106 splenocytes from animals treated with 1,25(OH)2D 3 up to the age of 200 days or from arachis-oil-treated control mice of similar age, were injected i.v., 24 h prior to the transfer of the diabetogenic cells. Mice were tested for glucosuria twice weekly and were considered diabetic following the above-described criteria.
Statistical analysis
Data are expressed as mean + SD. Comparison of the incidence of insulitis and diabetes between the two groups was performed using the chi-square test. Significance of differences between the groups concerning calcaemic effects immunological data were calculated using the Mann Whitney U-test or, for normally distributed data, the unpaired Student's t-test. Significance was defined at the 0.05 level.
Results
Prevention of insulitis and diabetes by 1,25(OH)2D3.
Confirming previous results, treatment with 1,25(OH)2D3 succeeded in reducing insulitis incidence from 81% (26 of 32 mice) in the control group to 58 % (21 of 36 mice) in the treated group (p < 0.05). Animals with as few as one pathological islet were considered to have insulitis. Also, the severity of inflammation in the islets of treated mice (2.1 + 1.4) was less than in the control group (3.2_+1.4; p <0.025). Treatment with 1,25(OH)2D3 not only reduced insulitis incidence, but more importantly also reduced the cummulative incidence of diabetes at the age of 200 days, from 56 % (18 of 32 mice) in the control group to 8 % (3 of 36 mice) in the treated group (p < 0.001) (Fig. 1) . The three mice that developed diabetes despite treatment with 1,25 (OH)2D3, did so later than the control animals.
General tolerance and effects on calcium metabolism.
All animals had good fur quality and were thriving. All mice were weighed weekly and no difference was seen in weight gain between the 1,25(OH)zD3 and the vehicle-treated group resulting in a similar weight at the age of 200 days (data not shown). As expected, calcaemia, determined 24 h after the final injection of 1,25(OH)zD3 (n = 36) was raised (2.5 + 0.2 vs 2.2 + 0.2 mmol/1 in the control group In = 32], p < 0.005) (Table 1) were apparently well tolerated and allowed for longterm treatment, the universal effects on bone were severe as reflected by a 50 % decrease in calcium content of the tibias of the 1,25(OH)zD3 treated mice (n = 36) [2.9 _+ 0.6 vs 6.2 + 1.1 mg calcium/tibia in the control group (n = 32), (mean _+ SD) p < 0.01]. This bone demineral•177 resulted in a spontaneous femur fracture in one test animal.
Effects ofl,25(OH)2D3
on the immune system. In order to understand the immune effects and potential mechanisms of action of long-term treatment with high doses of 1,25(OHhD3, immunological tests were performed at the age of 200 days in both treated and control nondiabetic mice 24h after the final injection of 1,25(OH)2D3 or arachis oil. Fluorescence activated cell sorting analysis of lymphocyte subsets (T lymphocytes, CD4, CD8, B-lymphocytes, NK cells) in spleen, thymus and lymph nodes revealed no significant differences in relative or absolute numbers between the two groups (markers analysed were Thyl.2, Lyt2, L3T4 (Becton Dickinson, Erenbodegem, Belgium), IgG + IgM (Jackson Labs, West Grove, Pa., USA) and ASGM-1 (Wako Chemicals, Neuss, Germany), respectively (data not shown). Although 1,25(OH)2D3 is a potent inhibitor of T-cell proliferation in vitro, long-term administration of 1,25(OH)zD3 in vivo did not result in severe immunosuppression, since splenocytes from both groups were able to proliferate normally in the allogeneic MLR as well as after anti-CD3 stimulation (Table 2) . Some known immune defects of NOD mice, such as defective NK-cell killing of YAC-1 targets [22] or defective thymocyte activation by anti-CD3 [23] were not corrected by 1,25 (OH)2D3 therapy.
The suppressor cell assay yielded the most interesting results: whereas control NOD mice could not generate suppressor cells in an autologous MLR, another known immune defect of the NOD mouse [21] , we observed a complete normal•177 of suppressor activity in the 1,25(OH)zD3 treated mice (Fig. 2) . The existence of suppressor cells was moreover confirmed in cell transfer experiments. Cotransfer of splenocytes from 1,25(OHhD3 treated animals significantly delayed and almost completely blocked diabetes transfer into na'fve irradiated young male NOD mice (p < 0.001 effect of splenocytes from 1,25(OH)2D3 treated NOD mice against diabetes transfer. Mice (6-8 week, irradiated 750 Red) receiving only splenocytes (20 x 106 iv) from overtly diabetic NOD mice (A) developed diabetes within 4 weeks after transfer (n = 7). No protective effect was seen when co-transfer was performed with splenocytes (20 x 106 iv) from normoglycaemic control mice (n = 6) (0, NS). Co-transfer with splenocytes from 1,25(OH)2D3 treated mice (n = 12), however, protected in the majority of cases against diabetes (A, p < 0.0001) demonstrating the existence of suppressor cells in these 1,25(OH)2D3 treated mice vs controls). Cotransfer with splenocytes from normoglycaemic age-matched (200 days) control NOD mice had no effect (Fig. 3) .
Discussion
The NOD mouse is a well-known animal model for the study of autoimmune diabetes (juvenile diabetes or IDDM). This autoimmune disease is characterized in mice and man by an infiltration of the islets of Langerhans in the pancreas resulting in a selective destruction of the insulin-producing beta cells. The cause of this insulitis and consequent diabetes is unknown, but in analogy with other autoimmune diseases, apart from faulty central tolerance induction, due to defective negative selection during T-cell development, and inaccurate energy induction, disruption of the balance between autoreactive cytotoxic T-cell clones and suppressor mechanisms (suppressor T cells) is an acceptable hypothesis [1-4]. Indeed, prevention of autoimmune diabetes in NOD mice can be achieved on the one hand by immunosuppressive treatments such as cyclosporin, FK 506, anti-lymphocyte serum or anti-L3T4 monoclonal antibodies [24] [25] [26] [27] , but on the other hand, also by immunostimulation, probably by restoring defective suppressor mechanisms [28] .
Both capacities, inhibition of effector T cells and stimulation of suppressor functions, have been at- The present study had a double purpose. First, to evaluate the potential of 1,25(OH)2D3 in the prevention of diabetes itself in NOD mice and secondly, to investigate the effects of long-term treatment with pharmacological doses of 1,25(OH)2D3 on the immune system.
Confirming previous results, 1,25(OH)2D3 reduced the incidence of insulitis significantly, but more importantly, clinical diabetes was even more drastically reduced.
Extensive immunological testing demonstrated again the short-term immunosuppressive action of 1,25(OH)2D3, since splenocytes of treated mice showed a normal response to alloantigen (tested in MLR) and to anti-CD3 stimulation, when tested 24 h after the final 1,25(OH)2D3 injection. This absence of long lasting immunosuppression, partly due to the fast metabolic clearance of the drug, could offer important advantages in clinical application, e. g. during intercurrent infections.
The most striking effect of 1,25(OH)2D3 was the complete normalisation of the suppressor activity in treated NOD mice. Whereas control mice showed a failure to generate suppressor cells in autologous MLR, a known defect in NOD mice, suppressor function became normal under treatment with 1,25(OH)2D3 [21] . This capacity of 1,25(OH);D3 to enhance the generation of suppressor cells has already been previously demonstrated in vitro [14] and interestingly, this ability to generate suppressor cells has also been reported for cyclosporin A, another immunomodulatory drug, known to prevent diabetes [32] . As demonstrated by Hess et el. [32] addition of cyclosporin to an allogeneic MLR hampers T-cell proliferation, but cannot completely block it and allows for the development of suppressor cells. NOD mice and other mouse strains prone to autoimmunity are unable to mount such suppressor cells in autologous MLR. Serreze et el. [28] demonstrated that by restoring this suppressor capacity, e. g. through treatment of these NOD mice with interleukin-2 or Poly IC, diabetes could be prevented. The authors suggested that these sup-
